Medicine composition for treating cerebral ischemia

A technology of anti-cerebral ischemia and composition, which is applied in the direction of drug combination, drug delivery, blood diseases, etc., and can solve the problems of large and unsafe drug use

Inactive Publication Date: 2007-06-27
GUIZHOU XINBANG YUANDONG PHARMACEUTICAL CO LTD
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to combine two drugs with different action mechanisms, which can significantly reduce the infarct area of ​​the brain tissue, and significantly reduce the behavioral disorder caused by brain tissue necrosis. Since the drug interaction is a synergistic interaction, it is stronger than a single drug The additive effect of the entity; solve the problem of high and unsafe drug dosage; make the drug curative effect faster and stronger
The purpose of the present invention is to address the above-mentioned deficiencies in the prior art, and provide a kind of pharmaceutical composition of anti-cerebral ischemia to people, mainly in order to solve the problem of using ginsenoside Rd or salvianolic acid B alone as a treatment for ischemic cerebrovascular disease. Various problems in diseases, specific receptors manipulate Ca 2+ Combined Use of Channel Blocker Ginsenoside Rd and Platelet Activating Factor Receptor Antagonist Salvianolic Acid B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] The preparation of embodiment 1 injection

[0014] 1. Prescription:

[0015] Ginsenoside-Rd 5g

[0016] Salvianolic acid B 5g

[0017] Sodium chloride 9g

[0018] 1,2-propanediol 100ml

[0019] Water for injection about 900ml

[0020]

[0021] Makes 1000ml

[0022] 2. Preparation:

[0023] Take ginsenoside-Rd, salvianolic acid B, sodium chloride, 1,2-propanediol; dissolve sodium chloride to 500ml of 20% propylene glycol aqueous solution, add ginsenoside-Rd, salvianolic acid B, and place on a water bath at 60-70°C Stir until completely dissolved, cool to room temperature, add the remaining amount of water for injection to 1000ml, mix well and filter with a 0.22μm filter membrane. The filtrate is filled in separate bottles, sealed, and sterilized to obtain the product.

Embodiment 2

[0024] The preparation of embodiment 2 dropping pills

[0025] 1. Prescription:

[0026] Ginsenoside Rd 2g

[0027] Salvianolic acid B 4g

[0028] Macrogol 6000 37g

[0029]

[0030] Makes 1000 capsules

[0031] 2. Preparation:

[0032] Take polyethylene glycol 6000, put it in a container, heat it to 70-80°C, wait until it is completely melted, and when the temperature drops to about 50°C, add ginsenoside Rd and salvianolic acid B to melt, and control the temperature at 40-50°C , pour it into a dripping pill machine for dripping, drop into simethicone oil, and make a dripping pill, that is to say.

Embodiment 3

[0033] Example 3 Preparation of Sublingual Tablets

[0034] 1. Prescription:

[0035] Ginsenoside Rd 20g

[0036] Salvianolic acid B 10g

[0037] Hydroxypropyl methylcellulose (E-50) 80g

[0038] Hydroxypropylmethylcellulose (E-4M) 50g

[0039] Hydroxypropyl Cellulose 20g

[0040] Micronized silica gel 3g

[0041] Magnesium Stearate 7g

[0042]

[0043] Makes 1000 pieces

[0044] 2. Take ginsenoside Rd, salvianolic acid B, hydroxypropyl methylcellulose (E-50), hydroxypropyl methylcellulose (E-4M), hydroxypropyl cellulose, micronized silica gel, stearic acid Magnesium is mixed uniformly by the method of increasing in equal amounts, and directly pressed into sublingual lozenges, that is, it is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is medicine composition for treating cerebral ischemia and its medicinal application. The medicine composition has ginsenoside and salvianolic acid as main components. It can reduce the cerebral infarction area obviously, reduce behavior disorder caused by cerebral tissue necrosis obviously, and reach the aim of treating cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vascular spasm, senile dementia, etc.

Description

Technical field: [0001] The invention relates to a compound composition with anti-cerebral ischemia effect, specifically, a combination of ginsenoside and salvianolic acid, which is an anti-cerebral ischemia drug, and belongs to the technical field of medicines. Background technique: [0002] Cerebrovascular disease has the characteristics of high morbidity, disability, mortality and recurrence, and is one of the biggest killers threatening human health. According to epidemiological surveys, the incidence of cerebrovascular diseases worldwide is 1.4-200 / 100,000 population, and the average death rate is 100 / 100,000 population. With the aging of the population, cerebrovascular diseases, especially ischemic cerebrovascular diseases, have become one of the major diseases that threaten human health. It has brought a heavy burden and has attracted widespread attention from all countries in the world. The mortality rate of cerebrovascular disease in my country has jumped to the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K9/00A61P9/10A61P7/02A61P3/06A61P25/28A61P25/16A61K31/343A61K31/335A61K31/216
Inventor 张观福杜健
Owner GUIZHOU XINBANG YUANDONG PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap